Rosacea: cross-border specialty drug access for international patients
Dermatology
ICD-10: L71
Quick orientation
Rosacea affects an estimated 5 percent of adults globally, with substantially higher prevalence in fair-skinned populations.
Typical age of onset. Most commonly between ages 30 and 50.
Severity tiers. Severity ranges from mild erythema and flushing to severe phymatous and ocular forms.
Why specialty drugs for Rosacea are hard to access internationally
Several newer topical formulations including minocycline foam and Emrosi (oral modified-release minocycline) have specific rosacea labels. International registration varies.
Treatments approved by the FDA
- Emrosi (minocycline hydrochloride extended-release capsules) — FDA approval: 2024. Mechanism: Tetracycline antibiotic in a modified-release oral formulation. Route: Oral once daily. US WAC ballpark: Approximately USD 4,000 to 6,000 per year. Country pricing: India · Lebanon.
Cross-border pathways used for Rosacea
Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:
What your physician needs to know
- Confirm subtype (erythematotelangiectatic, papulopustular, phymatous, ocular).
- Document failure or intolerance of standard topical agents.
- Counsel on triggers and skincare.
- Dermatologist co-management is recommended for severe forms.
Common questions
How does Emrosi differ from generic minocycline?
Emrosi is a modified-release formulation specifically labeled for rosacea, with a daily dose and tolerability profile distinct from immediate-release minocycline.
Is it available outside the US?
International registration is in early stages.
How long is a course?
Treatment continues based on response and tolerability.
What documents are required?
Dermatologist's prescription, clinical summary, and prior treatment history.
How long does shipment take?
Five to ten business days from prescription receipt.
Where Reserve Meds fits in
Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Rosacea, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.
We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.
Start a request
Reserved for you.